Translational gastroenterology and hepatology最新文献

{"title":"Pan-gastrointestinal adenocarcinoma analysis uncovers the prognostic and immune correlates of ferroptosis-related genes.","authors":"Xiaochuan Dong, Yanyan Xie, Wenxi Chen, Mengjiang He, Hua Liu, Bin Wang, Yu Xu, Qiaoxia Zhou, Tengfei Zhu, Guoqiang Wang, Chunwei Xu, Wenxian Wang, Shangli Cai, Meili Xu, Jingjing Wang","doi":"10.21037/tgh-24-15","DOIUrl":"10.21037/tgh-24-15","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal adenocarcinomas (GIACs) are common malignant tumors with poor prognosis in the world. Ferroptosis, characterized by the accumulation of intracellular iron and lipid reactive oxygen species, emerges as a pivotal process in tumorigenesis and cancer advancement. However, the implications of ferroptosis-related genes in GIAC remain to be elucidated. This study aimed at exploring the potential role of ferroptosis-related genes on the prognosis and treatment of GIAC.</p><p><strong>Methods: </strong>In our study, comprehensive clinical, transcriptomic, and/or genomic data were acquired from The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE), Genomics of Drug Sensitivity in Cancer (GDSC), and Gene Expression Omnibus (GEO). We formulated a ferroptosis-score within the TCGA cohort through gene set variation analysis (GSVA) and subsequently validated in 4 GEO datasets (GSE84437, GSE17536, GSE103479, and GSE19417). Drug sensitivity and immunotherapy efficacy were analyzed in the GDSC dataset and the PRJEB25780 cohort, respectively.</p><p><strong>Results: </strong>The ferroptosis-score was significantly associated with favorable overall survival both in the training cohort [TCGA: P=0.003; hazard ratio (HR), 0.67, 95% confidence interval (95% CI): 0.52-0.87] and across the four validation cohorts (GSE17536: P=0.03; HR, 0.57, 95% CI: 0.34-0.96; GSE19417: P=0.047; HR, 0.53, 95% CI: 0.28-1.01; GSE84437: P=0.004; HR, 0.68, 95% CI: 0.51-0.90; GSE103479: P=0.03; HR, 0.55, 95% CI: 0.32-0.96). Furthermore, the ferroptosis-score was correlated with activation of the DNA damage repair pathway and resistance to cisplatin. Notably, GIACs with low ferroptosis-scores exhibited heightened expression of immune checkpoint molecules such as programmed death-(ligand) 1 and cytotoxic T lymphocyte antigen-4, elevated densities of tumor-infiltrating CD8+ T cells, and a favorable response to pembrolizumab monotherapy.</p><p><strong>Conclusions: </strong>Our findings delineated the clinical relevance of ferroptosis-related genes in GIACs and demonstrated the potential utility of the ferroptosis-score in predicting prognosis and immunotherapy effectiveness.</p>","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"10 ","pages":"7"},"PeriodicalIF":3.8,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal combination regimen for a patient with advanced huge hepatocellular carcinoma: a case report.","authors":"Shan Li, Zhen-Feng Zhou, Hao-Jian Long, Jia-Xin Yin, Hui-Zhong Wang, Jian-Fu Zhao","doi":"10.21037/tgh-24-91","DOIUrl":"10.21037/tgh-24-91","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is a highly malignant tumor of the digestive system with a poor prognosis. Huge HCC, a subtype characterized by tumors measuring at least 10 cm in diameter, often presents with macrovascular invasion, satellite nodules, metastases, and other aggressive characteristics, posing significant challenges for treatment. The era of combined targeted therapy and immunotherapy has brought new hope to patients with advanced HCC. The development of innovative combination medication regimens for HCC is a current area of intense clinical research interest. We are trying to explore new combination therapies based on target-immunity combination therapy in the hope of better-benefiting patients with advanced huge HCC.</p><p><strong>Case description: </strong>We present a patient with Barcelona Clinical Liver Cancer Stage C huge HCC who was treated with combined targeted therapy and immunotherapy as the primary therapeutic regimen, supplemented with tegafur long-term metronomic chemotherapy, as well as specialized adjuvant therapy such as thymosin, bisphosphonates, antiviral medication, and vitamin C supplementation. The tumor size was significantly reduced and microwave ablation was performed, after which, the patient was kept on the combination regimen, resulting in a partial response (PR), and maintaining PR without disease progression for 32 months.</p><p><strong>Conclusions: </strong>The combination regimen may enhance advanced huge HCC treatment and provide a new multimodal drug strategy for HCC.</p>","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"10 ","pages":"17"},"PeriodicalIF":3.8,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic ultrasound-guided gastroenterostomy: a review.","authors":"Edwin Golikov, Jessica Widmer","doi":"10.21037/tgh-23-51","DOIUrl":"10.21037/tgh-23-51","url":null,"abstract":"<p><p>Gastric outlet obstruction (GOO) occurs due to anatomic blockage of the stomach or duodenum. GOO typically manifests with symptoms such as early satiety, nausea, vomiting, and weight loss, due to either underlying benign or malignant causes. Historically, the gold standard for managing GOO has been surgical gastrojejunostomy. However, this approach comes with considerable drawbacks including prolonged recovery times and the necessity for suitable surgical candidates. Endoscopically placed self-expanding metal stents emerged as a notable advancement in palliating symptoms associated with GOO. However, their long-term efficacy is hindered by the frequent occurrence of stent occlusion, necessitating the need for further intervention. Most recently, endoscopic ultrasound guided gastroenterostomy (EUS-GE) using lumen-apposing metal stents has been described with promising technical and clinical success rates. The advent of EUS-GE heralds a significant stride forward in the management of GOO, offering a less invasive yet effective alternative to conventional surgical approaches. EUS-GE has been associated with lower adverse events as compared with surgical gastrojejunostomy and lower recurrence and reintervention rates compared with enteral stenting. The advent of EUS-GE heralds a significant stride forward in the management of GOO, offering a less invasive yet effective alternative to conventional surgical approaches. EUS-GE is a promising evolving technique for treating GOO, and ongoing studies are necessary to validate its use in both benign and malignant GOO.</p>","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"10 ","pages":"13"},"PeriodicalIF":3.8,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unravelling risk factors for delayed bleeding following ultrasonography-guided liver biopsy: a retrospective analysis.","authors":"Tao Jiang, Qunying Li, Ju Li, Tianan Jiang","doi":"10.21037/tgh-24-79","DOIUrl":"10.21037/tgh-24-79","url":null,"abstract":"<p><strong>Background: </strong>Percutaneous liver puncture remains the gold standard for diagnosis of liver lesions, though image-guided techniques reduce the incidence of complications, there remains a risk of severe delayed bleeding. This study aimed to analyze the risk factors associated with delayed bleeding complications after ultrasonography-guided liver biopsy.</p><p><strong>Methods: </strong>In this retrospective study, we enrolled a total of 642 patients who underwent ultrasonography-guided percutaneous liver biopsy at our institution between January 2022 and December 2023. Data on patient characteristics, laboratory results, radiographic findings, bleeding complications, and treatments were extracted from the electronic medical records (EMR) system of the hospital. This study aimed to identify the differences in clinical characteristics between post-biopsy bleeding and non-bleeding groups as well as between early and delayed post-biopsy bleeding groups. Propensity score matching (PSM) algorithms were employed to mitigate the impact of sample size on the results.</p><p><strong>Results: </strong>After exclusion screening, a total of 627 patients were included in this study. Of these, 233 (37.16%) were men and 394 (62.84%) were women. The primary reason for liver puncture was liver transplantation (45.29%). Eleven cases of post-biopsy bleeding were observed, where eight were mild (72.73% of total cases exhibiting bleeding and 1.27% of total punctures) and three were serious (27.27% of total cases displaying bleeding and 0.48% of total punctures). Serious bleeding was delayed in all patients exhibiting bleeding. No bleeding-related risk factors were identified in either the overall cohort or the PSM cohort. Nevertheless, our findings indicate that patients with delayed bleeding exhibited lower platelet counts and were more likely to present with hydrothorax or ascites.</p><p><strong>Conclusions: </strong>There were no statistically significant differences in any of the baseline characteristics between patients with and without post-biopsy bleeding. However, when patients presented with platelets below the normal range in conjunction with hydrothorax or ascites, there was an increased risk of delayed bleeding.</p>","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"10 ","pages":"4"},"PeriodicalIF":3.8,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of hepatitis B virus reactivation prevention measures in immunosuppressed patients: current status and effectiveness.","authors":"Toru Ishikawa, Mitsuyuki Suzuki, Terasu Honma, Toshiaki Yoshida","doi":"10.21037/tgh-24-103","DOIUrl":"10.21037/tgh-24-103","url":null,"abstract":"<p><strong>Background: </strong>Prevention of hepatitis B virus (HBV) reactivation is a very important issue, but there is still no clear strategy. This study aimd to develop and evaluate an in-hospital collaboration flow to prevent HBV reactivation, guided by the Japanese Society of Hepatology (JSH) guidelines.</p><p><strong>Methods: </strong>We have strengthened and implemented a screening system and for HBV reactivation from February 2022 to January 2023. We assessed the administration of nucleic acid analogs (NAs) in hepatitis B surface antigen (HBsAg) or HBV DNA-positive cases, the detection rate of HBs or hepatitis B core (HBc) antibodies in HBsAg or HBV DNA-negative cases, and the follow-up status of HBV DNA testing. A total of 1,195 patients were included, with exclusions based on the judgement of no need for testing by the attending physician.</p><p><strong>Results: </strong>Among 1,172 tested patients, 1.88% (n=22) were HBsAg or HBV DNA-positive, all of whom received NA therapy. Among 1,150 HBsAg or HBV DNA-negative cases, 9.91% (n=114) were HBs or HBc antibody-positive, with 82.5% (n=94) undergoing HBV DNA testing. Over the years, the HBV DNA measurement rates increased significantly to 82.5% in 2022.</p><p><strong>Conclusions: </strong>The implemented screening regimen resulted in high and improving testing rates over time. Most HBsAg or HBV DNA-positive cases were treated with tenofovir alafenamide (TAF), highlighting its potential benefits in terms of safety and adherence. Continued validation and adaptation of the screening system are necessary to further prevent HBV reactivation.</p>","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"10 ","pages":"5"},"PeriodicalIF":3.8,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elimination of hepatitis C in the Middle East: a narrative review of the efficacy of direct-acting antiviral therapies.","authors":"Catherine Coxeter-Smith, Ria B Gaglani, Robert D Ingram, Oliver T Kidd, Anjana S Kumar, Amin Alhadad, Laith Alrubaiy","doi":"10.21037/tgh-24-87","DOIUrl":"10.21037/tgh-24-87","url":null,"abstract":"<p><strong>Background and objective: </strong>Hepatitis C virus (HCV), is a major health concern in the Middle East. Recent advances in direct-acting antivirals (DAAs) have transformed the treatment of HCV. The DAA chosen depends on the HCV genotype (GT) responsible for the infection, presence of cirrhosis, and prior treatment attempts. In addition, factors such as human immunodeficiency virus (HIV) co-infection and renal impairment can influence treatment. This literature review aims to discuss and appraise evidence on the efficacy and safety of the DAAs currently licensed for hepatitis C treatment in the Middle East.</p><p><strong>Methods: </strong>Supporting publications from the National Institute for Health and Care Excellence (NICE) and European Association for the Study of the Liver guidelines were searched manually. A literature search of PubMed, MEDLINE, Cochrane Library, and EMBASE databases was performed with search terms including 'HCV', 'clinical trial', and the seven combinations of DAA combinations recommended by NICE. Papers from January 2016 to January 2021 were considered, along with seminal papers outside this range.</p><p><strong>Key content and findings: </strong>Of 390 publications found, 62 were included. In most studies, DAAs showed high efficacy in the recommended GTs, cirrhosis states, and prior HCV treatments. DAAs were found to be generally safe and well-tolerated: the most common side effects throughout were headache and nausea. Serious adverse events (SAEs) were seen when ribavirin and peginterferon alfa were taken in combination with the DAA.</p><p><strong>Conclusions: </strong>This review demonstrates the strong evidence for the efficacy and safety of DAAs. The focus of HCV research should shift from efficacy of treatment to investigating accessible screening and diagnostics in order to achieve the World Health Organisation's (WHO's) goal of eradicating HCV by 2030.</p>","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"10 ","pages":"10"},"PeriodicalIF":3.8,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 13-year nationwide analysis of outcomes of non-variceal upper gastrointestinal bleeding in post-bariatric surgery patients.","authors":"James R Pellegrini, Andrej M Sodoma, Samuel Greenberg, Sonika Rathi, Nicholas Knott, Richard Pellegrini, Jaspreet Singh","doi":"10.21037/tgh-24-100","DOIUrl":"10.21037/tgh-24-100","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Non-variceal upper gastrointestinal bleeding (NVUGIB) is a common cause of hospitalization and associated morbidity and mortality. Bariatric surgery is a widely performed category of gastrointestinal (GI) surgery that attempts to induce weight loss by reconstructing the upper GI tract. Bleeding is a common complication of bariatric surgery; however, limited research exists on outcomes for these patients when admitted for NVUGIB compared to those without a history of bariatric surgery. Our study aims to evaluate the outcomes of post-bariatric surgery patients (PBSPs) admitted with NVUGIB over a 13-year span.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The National Inpatient Sample (NIS) from 2008 to 2020 was used to identify patients over 18 years old admitted for NVUGIB using the International Classification of Disease (ICD), 9&lt;sup&gt;th&lt;/sup&gt; revision (ICD-9) and 10&lt;sup&gt;th&lt;/sup&gt; revision (ICD-10) codes. Records were weighted using the algorithms provided by the NIS. Primary outcomes of interest were all-cause hospital mortality, shock, acute myocardial infarction (AMI), acute kidney injury (AKI), and a composite of these. Groups were defined based on the history of bariatric surgery, and demographics and incidence of comorbidities were compared. Outcomes were compared between the two groups, and odds ratios (ORs) were calculated using two-stage weighted logistic regression. ORs were adjusted for common co-founders such as age, gender, race, Charlson comorbidity index (CCI), region, hospital size, hospital teaching status, elective &lt;i&gt;vs.&lt;/i&gt; emergency admission, and income quartile.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 2,231,826 patients admitted for NVUGIB were included in this study. Of these, 28,167 had a history of bariatric surgery. Overall, bariatric surgery patients were younger, less complicated (CCI: 2.71 &lt;i&gt;vs.&lt;/i&gt; 4.76), had a shorter length of stay (LOS), and were less likely to be on Medicare/Medicaid than those without a history of bariatric surgery (P&lt;0.05). Several comorbidities were more common in patients without a history of bariatric surgery, including coronary artery disease, hyperlipidemia (HLD), congestive heart failure (CHF), type 2 diabetes mellitus (T2DM), end-stage renal disease (ESRD), and liver cirrhosis (P&lt;0.05). Other comorbidities were more common in the post-bariatric surgery group, including gastroesophageal reflux disease and anemia (P&lt;0.05). We found that patients admitted for NVUGIB with a history of bariatric surgery had significantly lower odds of all outcomes, including all-cause mortality (OR =0.48; P&lt;0.001), AKI (OR =0.71; P&lt;0.001), AMI (OR =0.62; P&lt;0.05), shock (OR =0.88; P&lt;0.05), and a composite of these four (OR =0.77; P&lt;0.001).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Our study found that patients with NVUGIB and a history of bariatric surgery had substantially decreased odds of mortality, AMI, shock, and AKI compared to patients without a history of bariatric surgery. This suggests","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"10 ","pages":"6"},"PeriodicalIF":3.8,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemopreventive strategies for sporadic colorectal cancer: a narrative review.","authors":"Savanna Monson, Pin-Jung Chen, Alexandra Gangi, Kevin Waters, Sandrine Billet, Andrew Hendifar, Shelly Lu, Jason A Zell, Jun Gong","doi":"10.21037/tgh-24-97","DOIUrl":"10.21037/tgh-24-97","url":null,"abstract":"<p><strong>Background and objective: </strong>Globally, colorectal cancer (CRC) is the third most commonly diagnosed cancer. CRC is known to arise from precancerous polyps known as adenomas. Although there are genetic syndromes (i.e., familial adenomatous polyposis syndrome) that carry a high lifetime risk of CRC, the majority of CRC cases are sporadic. Sporadic CRC develops via molecular events that occur early and frequently in the transformation of the normal colon epithelium to invasive cancer. Prevention of sporadic CRC (i.e., CRC chemoprevention) has been a topic of interest in the past decades due to its large public health burden. The objective of this study is to review various chemopreventive agents studied in randomized controlled trials (RCTs) to evaluate their effectiveness and safety in preventing sporadic CRC.</p><p><strong>Methods: </strong>This review focuses on recent RCTs using potential chemopreventive agents to prevent sporadic CRC formation, either directly or through reduction of its known precursors such as adenomas or aberrant crypt foci (ACF) through interventions including nonsteroidal anti-inflammatory drugs (NSAIDs), vitamins and minerals, and metabolic agents.</p><p><strong>Key content and findings: </strong>Multiple RCTs have been conducted in sporadic CRC chemoprevention. NSAIDs have proven promising in sporadic CRC chemoprevention but have been limited due to increased cardiovascular risk, particularly for celecoxib and rofecoxib.</p><p><strong>Conclusions: </strong>There is active investigation into establishing the first sporadic CRC chemoprevention strategy. Building from previous trials, the choice of study population, selection of endpoints, safety and tolerability, availability of surrogate biomarkers, and novel mechanisms of action targeting the adenoma-carcinoma sequence remain important points to consider for all future trials of sporadic CRC chemoprevention.</p>","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"10 ","pages":"11"},"PeriodicalIF":3.8,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The synthesis of the psychosocial and the physiological aspects of chronic digestive disease is at a crossroads.","authors":"Sara H Marchese, Tiffany H Taft","doi":"10.21037/tgh-24-102","DOIUrl":"10.21037/tgh-24-102","url":null,"abstract":"","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"10 ","pages":"1"},"PeriodicalIF":3.8,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decreased overall survival in patients with hepatocellular carcinoma during the COVID-19 pandemic.","authors":"Ulrike Bauer, Cornelia Fütterer, Rickmer F Braren, Petia Trifonov, Roland M Schmid, Katrin Böttcher, Ursula Ehmer","doi":"10.21037/tgh-24-54","DOIUrl":"10.21037/tgh-24-54","url":null,"abstract":"<p><strong>Background: </strong>The coronavirus disease-2019 (COVID-19) pandemic had a profound influence on screening, diagnosis and treatment of cancer patients worldwide. Due to overloaded health care facilities, screening and surveillance visits for early cancer detection were postponed or completely omitted. This included surveillance of patients with liver cirrhosis who are at risk for development of hepatocellular carcinoma (HCC) and resulted in a decrease in HCC diagnoses. We therefore aimed to analyze the impact of the COVID-19 pandemic on HCC diagnoses and survival of HCC patients in our tertiary care center in Germany.</p><p><strong>Methods: </strong>We conducted a monocentric retrospective study in which we analyzed data of 175 patients diagnosed with HCC before (March 2018 through February 2020) or during the COVID-19 pandemic (March 2020 through February 2022).</p><p><strong>Results: </strong>Compared to patients diagnosed with HCC prior to the COVID-19 pandemic, a significantly higher percentage of patients was diagnosed with HCC in more advanced stages during the COVID-19 pandemic. This was associated with a significantly lower overall survival (OS) in patients diagnosed with HCC during the first year of the pandemic. Importantly, stage-dependent survival was not different between patients diagnosed before and during the COVID-19 pandemic, strongly indicating that diagnostic delay during the pandemic did not play a major role at our center.</p><p><strong>Conclusions: </strong>Taken together, our data indicate that the COVID-19 pandemic significantly impacted on HCC patient care. Specifically, our data suggests that HCC diagnosis was delayed during the pandemic in a relevant percentage of patients translating into reduced survival in our patient cohort.</p>","PeriodicalId":94362,"journal":{"name":"Translational gastroenterology and hepatology","volume":"10 ","pages":"9"},"PeriodicalIF":3.8,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}